Tag: Incorporated

Latest Supply & Trading Agreement Represents Significant Progress Toward Company's Long-Term Objective of $1 Billion in Annualized Commercial Activity

Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
—Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe—

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce today that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), has entered into a binding memorandum of understanding (the “MOU”) setting out the principal commercial terms for a proposed definitive distribution agreement (the “Definitive Agreement”) with ExoLyra LLC, which operates as an arm’s length third party (“ExoLyra”).

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Stem Cell Culture Media Market size & share revenue was valued at approximately USD 765 Million in 2025 and is expected to reach USD 868 Million in 2026 and is expected to reach around USD 2714 Million by 2035, at a CAGR of 13.5% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are PAN Biotech GmbH, Sartorius AG, Cytiva, Lonza Group AG, Corning Incorporated, STEMCELL Technologies Inc., FUJIFILM Irvine Scientific Inc., Takara Bio Inc., Miltenyi Biotec B.V. & Co. KG, PromoCell GmbH, Biological Industries Ltd., CellGenix GmbH, Thermo Fisher Scientific Inc., HiMedia Laboratories Pvt. Ltd., Merck KGaA and others.

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the “Offering”).